The European Interleukin Inhibitors market is anticipated to grow significantly at a CAGR of 10.8% over the forecast period (2021-2027). The UK, Germany, France, Italy, Spain, and the Rest of Europe are the key economies contributing to the growth of the market over the forecast period. The key aspect that drives the growth of the European Interleukin Inhibitors market includes the well-established healthcare sector in the region. Besides, the rising prevalence of various diseases such as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others across the region. As per the Institute for Health Metrics and Evaluation, the prevalence of psoriasis was 12.3 million in 2017 which increased to 12.4 million in 2019.
To Request a Sample of our Report on European Interleukin Inhibitors Market: https://www.omrglobal.com/request-sample/europe-interleukin-inhibitors-market
The prevalence of asthma in the region in 2017 was more than 40.3 million which increased to 41.4 million in 2019. Whereas, the prevalence of inflammatory bowel disease (IBD) in 2017 was 1.5 million in 2017 which increased to more than 1.6 million in 2019. Further, the well-established healthcare sector in the region creates scope for market growth. There has been increased adoption of interleukin inhibitors for the treatment of such diseases. The IL-17 inhibitors function as angiogenesis; have a pro-inflammatory role in asthma; increases the inflammatory cytokines; and induces production of IL-4, IL-5, and IL-13, which stimulate eosinophil expansion. Hence, this is likely to drive the market growth over the forecast period.
(Get 15% Discount on Buying this Report)
A full Report of European Interleukin Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/europe-interleukin-inhibitors-market
Market Coverage
- Market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered- By Product Type and Applications
- Region Covered- Europe
- Competitive Landscape- Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among others
European Interleukin Inhibitors Market – Segmentation
By Product Type
- IL-1 Inhibitors
- IL-5 Inhibitors
- IL-6 Inhibitors
- IL-17 Inhibitors
- IL-23 Inhibitors
By Applications
- Arthritis
- Asthma
- Eczema
- Inflammatory Bowel Disease (IBD)
- Psoriasis
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
